Is there a Singapore original drug for Lurbinectedin?

Lurbinectedin is a targeted therapy drug used to treat recurrent small cell lung cancer and recurrent synovial sarcoma. It interferes with the survival and reproduction of cancer cells by affecting the topology of DNA, providing a new treatment option. Patients should discuss treatment options, expected results, and possible risks and side effects in depth with their doctor before receiving treatment so that they can make informed treatment decisions.

Rubicatin has not yet been launched in China, so it is not included in medical insurance. Patients cannot purchase it domestically and need to purchase Rubicatin through overseas channels. There is only the original drug Rubicatin in foreign countries, and the price is relatively expensive. In comparison, the original drug in Singapore is slightly cheaper, priced at more than 30,000, and there are other American versions of the original drug, priced at more than 90,000.

Rubicatine belongs to a class of drugs known asDNAtopoisomeraseIIα inhibitors. It interferes with the DNA repair and replication of cancer cells by affecting the topological structure of DNA, ultimately leading to cancer cell death. This mechanism of action makes it a targeted therapy, especially for cancer types that are less responsive to traditional treatments.

Rubicatine is usually given to patients through an intravenous injection. This means that patients need to be treated in a medical facility or hospital, where a doctor or health care worker will administer the injection. Injections usually require special training and equipment to ensure safety and effectiveness.

Rubicardin treatment may be associated with a range of side effects, including nausea, vomiting, fatigue, loss of appetite, blood problems (such as a decrease in white blood cells and platelets), abnormal liver function, heart problems, and other less common side effects. These side effects need to be monitored and managed during treatment to ensure patient health and safety.